Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. announced the retirement of its internal audit department head, Mr. Tang Yufeng, who will no longer hold any position in the company after his departure [1]. Group 1 - The board of directors received a written resignation report from Mr. Tang Yufeng due to retirement [1]. - Mr. Tang's resignation will take effect upon delivery to the board of directors, and it will not impact the company's normal operations [1]. - The board expressed gratitude for Mr. Tang's contributions during his tenure [1].

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Group 1 - The core point of the article is that Kangwei Century announced the resignation of its internal audit department head, Mr. Tang Yufeng, due to retirement, and he will no longer hold any position in the company after his departure [2] Group 2 - The announcement was made on February 2, indicating a formal communication from the company's board of directors regarding the leadership change [2] - Mr. Tang Yufeng submitted a written resignation report to the board, highlighting the procedural aspect of his departure [2]

证券代码：688426 证券简称：康为世纪 公告编号：2026-008 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特此公告。 江苏康为世纪生物科技股份有限公司 江苏康为世纪生物科技股份有限公司 关于内审部负责人退休离职的公告 近日，江苏康为世纪生物科技股份有限公司（以下简称"康为世纪"或"公司"）董事 会收到内审部负责人汤玉峰先生递交的书面离职报告。汤玉峰先生因退休原因辞去内审 部负责人职务，其离职后不再担任公司任何职务。 根据相关法规及《公司章程》等有关规定，上述离职报告自送达公司董事会之日起 生效。汤玉峰先生的离职不会对公司的正常生产经营产生影响，公司董事会将按照相关 规定聘任新的内部审计负责人。 公司董事会对汤玉峰先生在任职期间为公司发展所做的贡献表示衷心的感谢。 董事会 2026 年 2 月 3 日 1 / 1 ...

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

Group 1 - The company, 康为世纪 (688426.SH), announced that it expects to reduce its net loss attributable to shareholders in 2025 compared to the previous year [1] - The projected net loss for the company is estimated to be between -112 million and -91.44 million yuan, representing a year-on-year reduction in loss of 28.91% to 41.83% [1]

Core Viewpoint - The company expects to reduce its net loss for the fiscal year 2025 compared to the previous year, with a projected net profit attributable to the parent company ranging from -112 million to -91.44 million yuan, indicating a year-on-year reduction in loss of 28.91% to 41.83% [1] Financial Performance - The projected net profit attributable to the parent company for 2025 is estimated to be between -112 million yuan and -91.44 million yuan [1] - The expected reduction in loss is between 28.91% and 41.83% compared to the same period last year [1]

Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83% [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the performance change is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new businesses that have not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]

Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83 [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the change in performance is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new business which has not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]

Group 1 - The company Jiangsu Kangwei Century Biotechnology Co., Ltd. expects to reduce its net loss for the year 2025, projecting a net profit attributable to the parent company of approximately -112 million to -91.44 million yuan, representing a year-on-year reduction in loss of 28.91% to 41.83% [1] - The primary reason for the performance change is that the life sciences and diagnostic reagent industry is in a recovery phase [1] - The company is expanding into new business areas, which have not yet achieved economies of scale [1]